DK1663206T3 - 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist - Google Patents

1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist

Info

Publication number: DK1663206T3
Authority: DK; Denmark
Prior art keywords: agonist; imizadol; thione; sedative; dihydro
Prior art date: 2003-09-12

Application number

DK04781753T

Other languages

Danish (da)

English (en)

Inventor

Ken Chow

Todd M Heidelbaugh

John E Donello

Daniel W Gil

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-12

Filing date

2004-08-20

Publication date

2007-07-30

2004-08-20 Application filed by Allergan Inc filed Critical Allergan Inc

2007-07-30 Application granted granted Critical

2007-07-30 Publication of DK1663206T3 publication Critical patent/DK1663206T3/da

Links

239000000556 agonist Substances 0.000 title abstract 3
-1 2,3-Dimethyl-phenyl Chemical group 0.000 title 1
239000000932 sedative agent Substances 0.000 title 1
230000001624 sedative effect Effects 0.000 title 1
150000001408 amides Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000003937 drug carrier Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK04781753T 2003-09-12 2004-08-20 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist DK1663206T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50256203P	2003-09-12	2003-09-12
US10/891,953 US7141597B2 (en)	2003-09-12	2004-07-15	Nonsedating α-2 agonists
PCT/US2004/027134 WO2005034946A1 (en)	2003-09-12	2004-08-20	Nonsedating α-2 agonist 1- (2, 3-dimethyl-phenyl) -ethyl-1, 3-dihydro-imizadole-2-thione

Publications (1)

Publication Number	Publication Date
DK1663206T3 true DK1663206T3 (da)	2007-07-30

Family

ID=34278841

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04781753T DK1663206T3 (da)	2003-09-12	2004-08-20	1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
DK07006921.6T DK1800679T3 (da)	2003-09-12	2004-08-20	Ikke-sederende A-2 agonist 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imidazol-2-thione

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK07006921.6T DK1800679T3 (da)	2003-09-12	2004-08-20	Ikke-sederende A-2 agonist 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imidazol-2-thione

Country Status (25)

Country	Link
US (4)	US7141597B2 (de)
EP (2)	EP1800679B1 (de)
JP (1)	JP4698591B2 (de)
KR (1)	KR101145046B1 (de)
CN (1)	CN100417379C (de)
AT (2)	ATE358479T1 (de)
AU (1)	AU2004279332B2 (de)
BR (1)	BRPI0413719A (de)
CA (1)	CA2537832C (de)
CO (1)	CO5680444A2 (de)
CY (1)	CY1107608T1 (de)
DE (2)	DE602004005720T2 (de)
DK (2)	DK1663206T3 (de)
ES (1)	ES2285522T3 (de)
IL (1)	IL173530A (de)
MX (1)	MXPA06002668A (de)
NO (1)	NO20060667L (de)
NZ (1)	NZ545181A (de)
PL (2)	PL1663206T3 (de)
PT (1)	PT1663206E (de)
RU (1)	RU2345987C2 (de)
SI (1)	SI1663206T1 (de)
TW (1)	TWI337999B (de)
WO (1)	WO2005034946A1 (de)
ZA (1)	ZA200601002B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869079A (en) *	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en)	2000-07-05	2004-04-27	Oculex Pharmaceuticals, Inc.	Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) *	2000-11-29	2004-03-02	Oculex Pharmaceuticals, Inc.	Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7091232B2 (en) *	2002-05-21	2006-08-15	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) *	2002-05-21	2008-01-29	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) *	2002-05-21	2008-04-15	Allergan, Inc.	2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US20050048099A1 (en)	2003-01-09	2005-03-03	Allergan, Inc.	Ocular implant made by a double extrusion process
US7141597B2 (en) *	2003-09-12	2006-11-28	Allergan, Inc.	Nonsedating α-2 agonists
US20050059664A1 (en) *	2003-09-12	2005-03-17	Allergan, Inc.	Novel methods for identifying improved, non-sedating alpha-2 agonists
US20060293359A1 (en) *	2003-06-25	2006-12-28	Allergan, Inc.	Methods and compositions for the treatment of diabetes
US7812049B2 (en) *	2004-01-22	2010-10-12	Vicept Therapeutics, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050244469A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Extended therapeutic effect ocular implant treatments
EP1797043A1 (de) *	2004-09-24	2007-06-20	Allergan, Inc.	4-(phenylmethyl und substituiertes phenylmethyl)imidazol-2-thione, die als spezifische alpha2-adrenerge agonisten wirken
KR20070063016A (ko)	2004-09-24	2007-06-18	알러간, 인코포레이티드	알파2 아드레날린성 아고니스트로서 작용하는 4-(축합시클릭메틸)-이미다졸-2-티온
CA2603044A1 (en) *	2005-06-29	2007-01-11	Allergan, Inc.	Alpha-2 adrenergic agonists for the treatment of pain
US20070203144A1 (en) *	2006-01-17	2007-08-30	Allergan, Inc.	Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
BRPI0710674A2 (pt) *	2006-04-07	2011-08-23	Allergan Inc	composições incluindo fármacos relativamente insolúveis em água/não umectáveis e métodos para usar as mesmas
US20070298073A1 (en) *	2006-06-23	2007-12-27	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en)	2006-06-23	2014-08-12	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods
US20080153874A1 (en) *	2006-12-22	2008-06-26	Allergan Inc.	Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US8124774B2 (en) *	2007-05-23	2012-02-28	Allergan, Inc.	Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
PL2155733T3 (pl) *	2007-05-23	2013-02-28	Allergan Inc	Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego
US20110028559A1 (en) *	2007-07-06	2011-02-03	Fang Wenkui K	Substituted fluoroethyl ureas as alpha 2 adrenergic agents
JP2010536780A (ja) *	2007-08-15	2010-12-02	アラーガンインコーポレイテッド	治療化合物
AU2008286818B2 (en) *	2007-08-15	2014-03-27	Allergan, Inc.	Adrenergic compounds
KR20100071990A (ko) *	2007-08-15	2010-06-29	알러간, 인코포레이티드	녹내장 및 통증과 같은 질환의 처치에 유용한 헤테로사이클 치환된 융합 카르보사이클
WO2009052072A1 (en) *	2007-10-18	2009-04-23	Allergan, Inc.	Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US8455548B2 (en) *	2007-10-18	2013-06-04	Allergan, Inc.	Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052071A1 (en) *	2007-10-18	2009-04-23	Allergan, Inc.	Treatment of sensorimotor disorders with 4- ( 1- ( 2, 3 -dimethylphenyl) ethyl) -1h-imidaz0le-2 ( 3h) -thione
WO2009089448A1 (en) *	2008-01-11	2009-07-16	Allergan, Inc.	Therapeutic disulfide compounds for treating pain and diabetes
US20090264477A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc., An Indiana Corporation	Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en)	2008-04-18	2015-02-17	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9072727B2 (en)	2008-04-18	2015-07-07	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of degenerative disc disease
USRE48948E1 (en)	2008-04-18	2022-03-01	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable polymer
US8420114B2 (en) *	2008-04-18	2013-04-16	Warsaw Orthopedic, Inc.	Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090263451A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8889173B2 (en) *	2008-04-18	2014-11-18	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20120136035A1 (en)	2009-02-13	2012-05-31	Allergan, Inc.	4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US20100239632A1 (en)	2009-03-23	2010-09-23	Warsaw Orthopedic, Inc.	Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US9125902B2 (en) *	2010-01-28	2015-09-08	Warsaw Orthopedic, Inc.	Methods for treating an intervertebral disc using local analgesics
US9486500B2 (en)	2010-01-28	2016-11-08	Warsaw Orthopedic, Inc.	Osteoimplant and methods for making
US9050274B2 (en) *	2010-01-28	2015-06-09	Warsaw Orthopedic, Inc.	Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9060978B2 (en)	2011-01-24	2015-06-23	Warsaw Orthopedic, Inc.	Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9511077B2 (en)	2011-04-25	2016-12-06	Warsaw Orthopedic, Inc.	Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en)	2011-04-25	2017-03-14	Warsaw Orthopedic, Inc.	Medical devices and methods comprising an anabolic agent for treatment of an injury
KR20220002950A (ko)	2019-05-01	2022-01-07	클렉시오 바이오사이언시스 리미티드	소양증의 치료 방법
CN110894508B (zh) *	2019-10-31	2021-08-06	内蒙古大学	一种调控白色脂肪棕色化的基因Adra1a的应用
US20230404979A1 (en) *	2020-10-26	2023-12-21	Rush University Medical Center	Alpha-2 adrenergic receptor agonists to reduce mortality and improve outcomes in viral respiratory syndromes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63150266A (ja) *	1986-12-12	1988-06-22	Mitsui Petrochem Ind Ltd	ベンジルイミダゾ−ル誘導体
ZA881807B (en)	1987-03-20	1988-09-05	Merrell Dow Pharmaceuticals Inc.	Method for reducing reperfusion injury with imidazol-2-thiones
US4868197A (en)	1987-03-20	1989-09-19	Merrell Dow Pharmaceuticals Inc.	Reducing reperfusion injury with 1,3-dihydro-4-methyl-5-(4-methylthio)benzoyl)-2H-imidazol-2-thione
US4798843A (en) *	1987-07-09	1989-01-17	Smithkline Beckman Corporation	2-mercaproimidazole dopamine-β-hydroxylase inhibitors
GB2206880B (en) *	1987-07-16	1991-04-24	Farmos Oy	Optical isomers of an imidazole derivative
FR2706456B1 (fr) *	1993-06-18	1996-06-28	Rhone Poulenc Agrochimie	Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
EP0758323A1 (de)	1994-05-02	1997-02-19	Zeneca Limited	Herbizides hydroxylbenzyl-substituierte heteroarylverbindungen und deren derivate
PT1036065E (pt) *	1997-12-04	2004-09-30	Allergan Inc	Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
AR015744A1 (es) *	1998-04-01	2001-05-16	Orion Corp	Uso de dexmedetomidina para sedacion en terapia intensiva
US7091232B2 (en) *	2002-05-21	2006-08-15	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7141597B2 (en) *	2003-09-12	2006-11-28	Allergan, Inc.	Nonsedating α-2 agonists

2004
- 2004-07-15 US US10/891,953 patent/US7141597B2/en not_active Expired - Fee Related
- 2004-08-20 AT AT04781753T patent/ATE358479T1/de active
- 2004-08-20 BR BRPI0413719-1A patent/BRPI0413719A/pt not_active IP Right Cessation
- 2004-08-20 MX MXPA06002668A patent/MXPA06002668A/es active IP Right Grant
- 2004-08-20 CN CNB2004800262738A patent/CN100417379C/zh not_active Expired - Fee Related
- 2004-08-20 DE DE602004005720T patent/DE602004005720T2/de not_active Expired - Lifetime
- 2004-08-20 JP JP2006526107A patent/JP4698591B2/ja not_active Expired - Fee Related
- 2004-08-20 RU RU2006113600/04A patent/RU2345987C2/ru not_active IP Right Cessation
- 2004-08-20 EP EP07006921A patent/EP1800679B1/de not_active Expired - Lifetime
- 2004-08-20 AU AU2004279332A patent/AU2004279332B2/en not_active Ceased
- 2004-08-20 AT AT07006921T patent/ATE487477T1/de not_active IP Right Cessation
- 2004-08-20 PT PT04781753T patent/PT1663206E/pt unknown
- 2004-08-20 DE DE602004030051T patent/DE602004030051D1/de not_active Expired - Lifetime
- 2004-08-20 PL PL04781753T patent/PL1663206T3/pl unknown
- 2004-08-20 CA CA2537832A patent/CA2537832C/en not_active Expired - Fee Related
- 2004-08-20 DK DK04781753T patent/DK1663206T3/da active
- 2004-08-20 KR KR1020067005031A patent/KR101145046B1/ko not_active Expired - Fee Related
- 2004-08-20 WO PCT/US2004/027134 patent/WO2005034946A1/en not_active Ceased
- 2004-08-20 ES ES04781753T patent/ES2285522T3/es not_active Expired - Lifetime
- 2004-08-20 PL PL379561A patent/PL379561A1/pl unknown
- 2004-08-20 DK DK07006921.6T patent/DK1800679T3/da active
- 2004-08-20 NZ NZ545181A patent/NZ545181A/en not_active IP Right Cessation
- 2004-08-20 EP EP04781753A patent/EP1663206B1/de not_active Expired - Lifetime
- 2004-08-20 SI SI200430257T patent/SI1663206T1/sl unknown
- 2004-09-10 TW TW093127519A patent/TWI337999B/zh not_active IP Right Cessation
2006
- 2006-02-03 ZA ZA200601002A patent/ZA200601002B/en unknown
- 2006-02-05 IL IL173530A patent/IL173530A/en active IP Right Grant
- 2006-02-10 NO NO20060667A patent/NO20060667L/no not_active Application Discontinuation
- 2006-02-21 CO CO06017219A patent/CO5680444A2/es unknown
- 2006-07-20 US US11/458,731 patent/US7312238B2/en not_active Expired - Lifetime
2007
- 2007-06-21 CY CY20071100823T patent/CY1107608T1/el unknown
- 2007-12-18 US US11/959,356 patent/US20080176918A1/en not_active Abandoned
2010
- 2010-09-09 US US12/878,593 patent/US8022226B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN100417379C (zh)	2008-09-10
CA2537832A1 (en)	2005-04-21
RU2006113600A (ru)	2007-11-10
CA2537832C (en)	2012-01-24
EP1800679A2 (de)	2007-06-27
WO2005034946A1 (en)	2005-04-21
TWI337999B (en)	2011-03-01
US20070004790A1 (en)	2007-01-04
MXPA06002668A (es)	2006-06-06
ATE487477T1 (de)	2010-11-15
RU2345987C2 (ru)	2009-02-10
EP1800679B1 (de)	2010-11-10
AU2004279332B2 (en)	2010-10-07
IL173530A0 (en)	2006-07-05
EP1663206B1 (de)	2007-04-04
ATE358479T1 (de)	2007-04-15
NZ545181A (en)	2009-07-31
EP1800679A3 (de)	2009-01-21
NO20060667L (no)	2006-04-06
CY1107608T1 (el)	2013-03-13
TW200526591A (en)	2005-08-16
PL1663206T3 (pl)	2007-08-31
DE602004005720D1 (de)	2007-05-16
PL379561A1 (pl)	2006-10-16
KR101145046B1 (ko)	2012-05-21
DE602004030051D1 (de)	2010-12-23
HK1104979A1 (en)	2008-02-01
ZA200601002B (en)	2007-04-25
US7141597B2 (en)	2006-11-28
US20050059721A1 (en)	2005-03-17
JP4698591B2 (ja)	2011-06-08
SI1663206T1 (sl)	2007-06-30
KR20060119970A (ko)	2006-11-24
AU2004279332A1 (en)	2005-04-21
US8022226B2 (en)	2011-09-20
IL173530A (en)	2010-05-31
DK1800679T3 (da)	2011-02-07
EP1663206A1 (de)	2006-06-07
ES2285522T3 (es)	2007-11-16
JP2007505111A (ja)	2007-03-08
US7312238B2 (en)	2007-12-25
US20080176918A1 (en)	2008-07-24
CO5680444A2 (es)	2006-09-29
BRPI0413719A (pt)	2006-10-17
HK1092704A1 (en)	2007-02-16
CN1849118A (zh)	2006-10-18
US20110034525A1 (en)	2011-02-10
PT1663206E (pt)	2007-06-22
DE602004005720T2 (de)	2007-12-27

Publication	Publication Date	Title
DE602004005720D1 (de)	2007-05-16	1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imidazol-2-thion als nicht-sedierender alpha 2a agonist
ATE406360T1 (de)	2008-09-15	Antagonisten der opioidrezeptoren
NO2020010I1 (no)	2020-05-13	fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat
EA200401169A1 (ru)	2005-04-28	Аминометилзамещенные тетрациклиновые соединения
BR0308452A (pt)	2006-06-06	composições farmacêuticas e métodos de preparação de composição farmacêutica
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
CY1111867T1 (el)	2015-11-04	Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
CY1122429T1 (el)	2021-01-27	Αμορφη υδροχλωρικη λερκανιδιπινη
ATE308522T1 (de)	2005-11-15	Opioidrezeptorantagonisten
DE602005027540D1 (de)	2011-06-01	Feste formulierungen von ospemifen
EA200400280A1 (ru)	2004-08-26	Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
EP2394992A3 (de)	2012-03-21	Substituierte Piperidinverbindungen und Verfahren zu deren Verwendung
HRP20080057T3 (en)	2008-02-29	9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
NO20054787D0 (no)	2005-10-18	Indenderivater som farmasotiske midler
NO20014855D0 (no)	2001-10-05	N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ATE489096T1 (de)	2010-12-15	Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
BRPI0406734A (pt)	2005-12-20	Composição termiticida, e, método para controlar térmitas
DK1619185T3 (da)	2011-07-18	4,4-difluor-1,2,3,4-tetrahydro-5H-1-benzazepinderivat eller salt deraf
NO994135L (no)	1999-10-22	Kinoksalindioner
ATE491709T1 (de)	2011-01-15	Pyrrolidinohydrochinazoline
CO5560535A2 (es)	2005-09-30	Formulacion de medicamento que contiene un agonista ltb4